Phasiq, an Ann Arbor, Michigan-based healthcare company that provides a solution to test for multiple proteins on a single patient sample, raised funding.
The amount of the deal was not disclosed.
The Zell Lurie Commercialization Fund, in collaboration with the Samuel Zell & Robert H. Lurie Institute for Entrepreneurial Studies at the University of Michigan’s Stephen M. Ross School of Business, has invested in the company.
The company intends to use the funds to automate its manufacturing process to allow for scalable production of the finished first product.
Founded by Shuichi Takayama, professor of biomedical engineering and macromolecular science and engineering, and member of the Biointerfaces Institute and Center for Integrative Research in Critical Care at the University of Michigan, and led by new CEO Francis Glorie, Phasiq provides scientists and clinicians with a way of identifying multiple proteins in one culture sample, giving them a holistic view of the overall picture of a person’s health. This allows scientists to quickly complete research to develop new drugs and enables clinicians to test for and diagnose multiple diseases at the same time.
The Zell Lurie Commercialization Fund is a pre-seed investment fund established to identify and accelerate the commercialization of ideas generated within the University community and the surrounding area with a focus on healthcare, technology, consumer and cleantech. It is one of four student-led investment funds at the University that operates under the direction of the Zell Lurie Institute, which also include the flagship Wolverine Venture Fund, Social Venture Fund and newly-formed Zell Early-Stage Fund.